A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by 18% over one year. This effect is likely due to the drug’s ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimer’s biomarkers.

New research reveals that highly accurate blood tests for Alzheimer's can improve diagnosis accuracy and expedite treatment and research participation. These tests measure biomarkers like phosphorylated tau, which correlate with cognitive decline and brain atrophy.